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Making sense of oesophageal
contents
Mark Fox, Werner Schwizer
Everybody experiences gastro-oesophageal
reflux on occasion. In health, reflux of air
(‘‘belching’’) occurs most commonly during
‘‘transient lower oesophageal sphincter
relaxations’’ (TLOSRs) triggered by gastric
distension. Acid secretions and semi-
digested food may also pass into the
oesophagus during such events. Gastro-
oesophageal reflux disease (GORD) is pre-
sent when this reflux of gastric contents
causes symptoms or mucosal damage.1
GORD patients do not necessarily have
more TLOSRs than healthy controls.2
Rather, structural degradation and instabil-
ity of the gastro-oesophageal junction
increase the likelihood of reflux during
TLOSRs and at other times (e.g. on
straining).3 4 It is likely that the same
changes allow greater volumes of gastric
contents to pass the reflux barrier and to
extend further into the oesophagus.5 6 Once
reflux has occurred, ineffective motility and
clearance are also important because pro-
longed exposure to acid and other noxious
substances in refluxate (e.g. bile salts,
pepsin) increase the risk of erosive reflux
disease (ERD), Barrett’s columnar lined
oesophagus (CLO) and other complica-
tions.7 8 Whether reflux triggers patient
symptoms depends on a dynamic interac-
tion between several factors, including
patient age and sex, dietary factors, the
volume, composition and distribution of
the refluxate, mucosal disease, visceral
sensitivity, and central factors including
stress and patient vigilance (see box).5–20
Oesophageal pH testing was popularised
by Johnson and DeMeester in the belief
that GORD was not a symptom driven
condition, but should be diagnosed by
measurement of objective pathology.21 On
this basis, the condition was conceived as a
continuous spectrum of disease because
oesophageal acid exposure is associated
with the severity of symptoms and oeso-
phagitis.22 Nevertheless, the relationship
between reflux events, acid exposure,
endoscopic findings and symptoms is not
straightforward.13 For example, patients
with Barrett’s CLO often have high levels
of acid exposure but few symptoms
because the metaplastic, columnar lining
of the oesophagus is relatively insensitive
to acid.23 Conversely, severe symptoms and
a relatively poor response to acid suppres-
sion are often reported by patients with
normal or near-normal acid exposure and
without mucosal injury on conventional
endoscopy.24 25
Ambulatory 24 h pH monitoring remains
the standard investigation of GORD;26
however, it seems obvious that the value
of pH studies is limited in patients in whom
symptoms are not due to acid reflux. Multi-
channel intra-luminal impedance (MII)
detects and follows the movement of
oesophageal contents and can distinguish
fluid and gas within the lumen.27 Combined
pH and impedance monitoring has shown
that proton pump inhibitors (PPIs) reduce
acid reflux but have no effect on the
number of reflux events per se.28 Moreover,
clinical studies have found that weakly acid
or non-acid reflux is a common cause of
persistent symptoms in patients on PPI
treatment,29 including those with atypical
symptoms and chronic cough.30 31 These
findings led to rapid adoption of this
technique in clinical practice; however, the
analysis of MII data is time consuming and
its place in the routine investigation of
GORD is still being defined.
In this edition of Gut, Emerenziani and
colleagues (see page 443) compare the
findings of combined pH and impedance
monitoring in patients with ‘‘endoscopy
negative reflux disease’’ (ENRD), to those
with ERD and healthy controls.14 Overall,
and consistent with previous studies,29 32
about 80% of patient reports of heartburn
and regurgitation were related to acid
reflux. Moreover, the frequency of acid
reflux as a proportion of all the reflux events
was twice as high in patients than controls,
adding to the evidence that increased gastric
acid production, abnormal distribution of
secretions or delayed gastric emptying play
an important role in GORD.7 33
Oesophageal acid exposure was lower in
ENRD than ERD; in contrast, the percen-
tage association of reflux events with
symptoms (symptom index) was higher
for both acid and weakly acid reflux. On
detailed analysis it was found that only a
small proportion of symptoms (12%) were
triggered by weakly acid reflux in ERD
patients; however, this was significantly
higher in ENRD patients (22%), especially
in the subgroup with physiological oeso-
phageal acid exposure (32%). In addition,
and independent of acid content, the
presence of gas in the refluxate (i.e. mixed
reflux) increased the likelihood that symp-
toms were reported in ENRD patients,
almost certainly because of increased reflux-
ate volume and oesophageal distension. The
importance of these findings is not to
suggest that the acquisition of more and
more complex information about oesopha-
geal contents improves the diagnostic yield
of GORD. Rather it is to emphasise that
patients with a sensitive oesophagus can
experience typical reflux symptoms in
response to chemical or mechanical stimu-
lation in the clinical setting, and that a high
symptom index is a surrogate marker for
visceral hypersensitivity and/or abnormal
central processing of visceral sensations. As
explained below, this insight may be of
value in interpreting reflux studies and
predicting the outcome of treatment.
Before recommending that combined pH
and impedance replace conventional pH
monitoring, technical factors that affect
published comparison should be considered.
Firstly, the use of antimony pH electrodes
rather than ‘‘reference standard’’ glass elec-
trodes in most studies (and most commer-
cial catheters) could bias results. In clinical
practice the diagnostic agreement between
these systems is acceptable;34 35 however, pH
measurements acquired by antimony elec-
trodes (with external reference) drift
upwards over time due to oxidation in acid
environs.36–38 As a consequence, antimony
electrodes may register less ‘‘acid reflux’’
events than glass electrodes, especially when
gastric pH is elevated in the post-prandial
period and on PPI treatment. Secondly, the
recording characteristics and signal proces-
sing of pH and MII systems are fundamen-
tally different. The former provides a
continuous assessment of oesophageal acid
exposure. Each pH measurement represents
the mean acid exposure over a period of time
(typically 6 s), with reflux events recorded
after two consecutive readings under pH 4
(i.e. 12 s). The latter detects discrete acid and
non-acid reflux events, but does not provide
an assessment of ‘‘refluxate exposure’’
because current MII techniques are insensi-
tive to volume change.39 In addition, impe-
dance measurements are acquired at 50 Hz
and reflux events are identified by a char-
acteristic distal to proximal impedance fall
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(liquid) or rise (gas).40 Semi-automatic MII
analysis software identifies reflux events,
typically by an impedance fall .50% from
baseline to ,1000 V; however, findings
must be checked manually and the baseline
is routinely adjusted to increase sensitivity.
A similar approach to pH data would allow
rapid falls in pH that do not reach the pH 4
threshold to be counted as reflux events, an
approach that identifies many symptom-
associated reflux events currently detected
‘‘only’’ by MII, especially weakly acid reflux
in patients on PPI treatment.52 Studies are
needed that compare a similarly rigorous
analysis of pH and MII data.
A further limitation of many studies is
that reflux symptoms are not assessed
independently of the pH and impedance
measurements by validated questionnaire.
The relationship between oesophageal acid
exposure, symptom–reflux association and
overall symptom severity is not clear.
Patients with ERD or Barrett’s CLO and
severe, prolonged oesophageal acid exposure
often describe long periods of burning chest
and epigastric discomfort, information that
cannot be easily recorded by data loggers
(especially at night), resulting in a low
symptom index. In contrast, patients with
ENRD and mild acid exposure more often
experience discrete symptoms with reflux
events, resulting in a high symptom index.
This issue and the high day-to-day varia-
bility of symptoms probably explain why
symptom–reflux association tests do not
reliably predict the response to PPI treat-
ment in unselected patients.28 An alterna-
tive approach is to consider the severity of
oesophageal acid exposure and association
of reflux events and symptoms (e.g. symp-
tom index) as independent factors affecting
overall symptom severity. Accordingly, pH
monitoring provides a direct assessment of
disease severity in terms of acid exposure,
whereas symptom index (assessed by pH
and/or MII monitoring) provides an assess-
ment of visceral sensitivity to reflux events
(fig 1). This approach is supported by a
recent analysis of reflux and symptom
events during 96 h wireless pH monitor-
ing.41 As expected, symptom severity off
treatment increased with oesophageal acid
exposure (fig 2A). Almost all patients
improved to some extent on high dose PPI
treatment; however, the response was
inversely correlated to symptom index
(fig 2B). Thus, independent of oesophageal
acid exposure, patients with a high symp-
tom index (i.e. visceral hypersensitivity)
were more likely to experience persistent
symptoms on treatment due to weak acid
and/or mechanical distension by persistent
reflux episodes.41 These observations
explain the paradox that patients with
severe oesophageal acid exposure and muco-
sal disease often have a low symptom index
but respond well to acid suppression,
whereas patients with ENRD and func-
tional heartburn with a high symptom
index often continue to experience symp-
toms on treatment. Classification of
patients on this basis is consistent with
the shift in conceptual framework from
GORD as a continuous spectrum of disease,
to ENRD, ERD and Barrett’s CLO as
different pathophysiological responses to
acid exposure.1 15 At the same time it allows
for some movement between ENRD and
ERD observed in large longitudinal
trials,20 42 as oesophageal acid exposure and
visceral sensitivity vary over time with age,
weight, stress and other factors.
In summary, research with combined pH
and MII monitoring is slowly ‘‘making
sense’’ of oesophageal contents and the
occurrence of reflux symptoms; however,
in clinical practice it is not clear whether
this technique should be used routinely or
reserved for special indications. Current
guidelines advise a ‘‘treat and test’’
approach with further investigation by
endoscopy and physiological measurement
reserved for patients that fail to respond to
acid suppression.43 A small number (,2%)
of patients (higher in Asian populations)
have persistent acid reflux on treatment
due to mutations in the cytochrome
enzymes that metabolise PPIs.44 More
Figure 1 A model of GORD is presented in which the severity of oesophageal acid exposure and
association of reflux events and symptoms (e.g. symptom index) are independent factors effecting
overall symptom severity and treatment response.
Factors associated with patient reports of reflux events
c Patient demographics9–11
– age
– sex
– ethnicity
c Refluxate composition (chemical stimulation)13 14
– acid/pH
– bile salts/pepsin (more relevant for mucosal injury)
– liquid/gas (interacts with volume and distribution)
c Refluxate volume/distribution (mechanical stimulation)5 6
– Oesophageal sensitivity increases distal to proximal (laryngo-pharyngeal structures
very sensitive)
c Endoscopic findings14 15
– Increased in ENRD and functional heartburn
– Decreased in Barrett’s CLO
c Peripheral visceral sensitisation12 13 20
– Previous acid exposure
– Inflammation
– Dietary fat
– Alcohol
c Central factors18 19
– Acute stress
– Somatisation
– Vigilance
– Psychiatric morbidity
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commonly, persistent symptoms are
reported by patients with hiatus hernia
due to regurgitation of large volumes of
gastric content and those with ENRD and
functional heartburn due to hypersensitiv-
ity to ongoing reflux. Physiological studies
are rarely needed to confirm the diagnosis
in the former group unless fundoplication
surgery is under consideration. In contrast,
patients with no endoscopic findings often
require investigation as ‘‘atypical’’ symp-
toms are common in these individuals and,
conversely, reflux is not necessarily the
cause of ‘‘typical’’ symptoms.29 The com-
bined pH and MII technique is ideal for this
indication; however, detailed assessment of
the refluxate as described by Emerenziani
and colleagues is not usually required as
symptoms are not specific for oesophageal
contents.14 Alternatively, applying the
approach described above, pH studies alone
may be adequate to detect oesophageal
hypersensitivity if the recording is exam-
ined in detail to detect weakly acid reflux
(pH 4–5), thus increasing the sensitivity of
conventional symptom–reflux assessment.
Indeed prolonged pH monitoring by wire-
less pH measurement may be preferable,
especially in patients with intermittent
symptoms.45 A study directly comparing
the diagnostic yield of 24 h combined pH–
impedance and 48 h wireless pH measure-
ment is currently in progress.
Ultimately, the goal of investigation is to
improve patient care. Previously, GORD
treatment was directed towards healing
mucosal injury. More recently, there has
been a shift to controlling symptoms.
Patients with ENRD with an incomplete
response to PPIs have a form of functional
bowel disease and, in common with these
conditions, effective treatment can be direc-
ted not only at reducing the stimulus by acid
suppression, but also at reducing visceral
hypersensitivity. For those with ERD the
aim will be ‘‘complete remission’’ of symp-
toms and mucosal disease, whereas in
Barrett’s CLO the priority is to prevent
progression to dysplasia and malignancy.
This change of focus and the improved
ability to identify the causes of symptoms
and disease using modern physiological
measurement will benefit patients by direct-
ing effective treatment on an individual
basis.
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The significance of the gut
barrier in disease
Jon Meddings
In the paper by Wapenaar et al (see page
463) the authors have taken a fascinating
approach to identifying shared mechan-
isms involved in the genesis of either
coeliac disease or inflammatory bowel
disease (IBD).1 They argue that in these
two prototypical inflammatory diseases
of the intestinal mucosa there exists
reasonable evidence for a defect in barrier
function that appears to be required
before the development of disease.
Furthermore, as both diseases have strong
genetic components they speculated that
these syndromes might share common
genetic defects in the control of intestinal
barrier function. They used a genetic
association analysis approach and through
this identified two adapter protein coding
genes that were associated with coeliac
disease in patients from both Great
Britain and The Netherlands. They went
on to demonstrate that one of these genes
was also associated with ulcerative colitis
in a Dutch patient cohort.
These observations are important not
only for the conclusions reached in the
paper but also in the broader context.
Until recently, it was believed that IBD,
such as Crohn’s disease, represented dys-
regulation of the adaptive immune sys-
tem. Over the past decade, however, there
has been increasing recognition of the
importance of both epithelial barrier
function and innate immunity in the
genesis of intestinal inflammation. In the
broadest sense these two factors could be
argued to be different aspects of the same
basic system. Within the gastrointestinal
tract there is significant exposure to
foreign compounds that can drive sys-
temic inflammation through a variety of
mechanisms. The gut has a tremendous
number of defence mechanisms that have
evolved to manage this ever-changing
threat (fig 1). In general terms these
include the ability to manage commensal
flora in preference to pathogenic organ-
isms, the secretion of toxic molecules such
as defensins, the scavenging and binding
of luminal organisms by specifically for-
mulated mucins, the presence of regulated
tight and adherens junctions between
epithelial cells that regulate the passage
of potentially pro-inflammatory mole-
cules and the presence of both intra and
extracellular pattern recognition mole-
cules that can regulate immunological
responsiveness to environmental stimuli.
Finally, the adaptive immune system,
which sits on top of this large defensive
system, can fine tune the responses to a
wide variety of environmental agents. It is
an amazingly complex system that in
most of us functions extremely well!
Given the complexity of this defensive
system, however, it is not at all surprising
that defects in many of these impor-
tant systems could ultimately lead to
inflammatory disease. Furthermore, as
the mucosal immune system is ‘‘edu-
cated’’ primarily in the gut and these cells
subsequently migrate elsewhere, it is
perhaps not surprising that defects in
these systems may lead to inflammatory
disease that can be expressed at sites
distant to the intestine. This is becoming
increasingly apparent in human disease
and in animal models of disease.
It is beyond the scope of this commen-
tary to review each aspect of mucosal
defence exhaustively and there have been
excellent reviews recently.2 I would, how-
ever, like to discuss one aspect of gut barrier
function; that being abnormal epithelial
permeability and disease. The genetic
abnormalities described in this paper would
appear to fit most closely with this system.
Abnormal permeability refers to a
measurable increase in flux of small
water-soluble compounds across the para-
cellular pathway of the small intestine.
The rate of movement across this path-
way is regulated primarily by the func-
tional state of the tight and adherens
junction. These, in turn, are controlled by
a complex array of intracellular proteins
within the enterocyte as well as the
protein composition of the junctions
themselves. Increased permeability can
be observed as a result of action by
inflammatory cytokines (such as tumour
necrosis factor a, IL17 or IFN-c), bacterial
interactions with the enterocyte, migra-
tion of inflammatory cells across the
epithelium, nutrient transporter activa-
tion, noxious environmental agents or it
may exist de novo, without apparent
cause.3–6 In the latter case this may be
secondary to an alteration in the protein
composition of the junctions or presum-
ably their regulatory systems. In the paper
by Wapenaar et al,1 in this issue of Gut, it
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